TD Asset Management Inc Sells 74,610 Shares of Medtronic PLC $MDT

TD Asset Management Inc reduced its stake in Medtronic PLC (NYSE:MDT) by 6.7% during the 4th quarter, HoldingsChannel reports. The fund owned 1,042,603 shares of the medical technology company’s stock after selling 74,610 shares during the quarter. TD Asset Management Inc’s holdings in Medtronic were worth $100,152,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Cibc World Market Inc. lifted its position in Medtronic by 17.0% in the 4th quarter. Cibc World Market Inc. now owns 419,242 shares of the medical technology company’s stock valued at $40,272,000 after acquiring an additional 60,804 shares in the last quarter. Sivia Capital Partners LLC grew its stake in shares of Medtronic by 72.2% during the 4th quarter. Sivia Capital Partners LLC now owns 9,232 shares of the medical technology company’s stock worth $887,000 after acquiring an additional 3,872 shares in the last quarter. WCG Wealth Advisors LLC grew its stake in shares of Medtronic by 150.1% during the 4th quarter. WCG Wealth Advisors LLC now owns 67,780 shares of the medical technology company’s stock worth $6,511,000 after acquiring an additional 40,683 shares in the last quarter. Nvest Financial LLC grew its stake in shares of Medtronic by 23.1% during the 4th quarter. Nvest Financial LLC now owns 11,071 shares of the medical technology company’s stock worth $1,063,000 after acquiring an additional 2,079 shares in the last quarter. Finally, Avestar Capital LLC grew its stake in shares of Medtronic by 3.1% during the 4th quarter. Avestar Capital LLC now owns 8,277 shares of the medical technology company’s stock worth $795,000 after acquiring an additional 251 shares in the last quarter. 82.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. BTIG Research set a $90.00 price target on shares of Medtronic and gave the stock a “buy” rating in a research report on Wednesday. Mizuho cut their price target on shares of Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a research report on Wednesday. Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Evercore set a $106.00 price target on shares of Medtronic and gave the stock an “outperform” rating in a research report on Thursday, April 9th. Finally, Robert W. Baird cut their price target on shares of Medtronic from $93.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday. Sixteen research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $98.70.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic beat fiscal Q4 revenue and earnings estimates, driven by strong demand in cardiovascular devices, cardiac ablation, and medical-surgical products, which helped fuel the stock’s rebound.
• Positive Sentiment: The company raised its quarterly dividend to $0.72 per share, signaling confidence in cash generation and rewarding income-focused investors.
• Positive Sentiment: Management highlighted expanded Hugo robotic-assisted surgery filings and FDA activity, suggesting additional growth opportunities in surgical robotics. Medtronic submits 510(k) filings to expand Hugo robotic-assisted surgery system into general and gynecologic specialties in the United States
• Positive Sentiment: Several analysts maintained or upgraded bullish views, including BTIG’s upgrade to Buy and TD Cowen’s reiterated Buy, reinforcing optimism after the earnings beat. Wall Street May Be Mispricing Medtronic, Analyst Says
• Neutral Sentiment: Some analysts trimmed price targets while keeping neutral or hold ratings, including JPMorgan, Piper Sandler, Goldman Sachs, Baird, and Deutsche Bank, which reflects more cautious valuation views rather than a major change in the long-term story.
• Neutral Sentiment: Medtronic is also managing cardiovascular device recalls tied to sterile barrier concerns, creating an ongoing overhang even as newer product launches gain traction.
• Negative Sentiment: FY2027 EPS guidance came in slightly below the consensus estimate, and management noted tariff-related and margin pressure concerns, which may limit further upside. MDT Q4 Earnings Call Points to Another Year of Growth

Medtronic Stock Up 5.1%

Medtronic stock opened at $81.95 on Friday. The firm has a market capitalization of $105.22 billion, a PE ratio of 21.97, a P/E/G ratio of 1.89 and a beta of 0.58. The company’s 50-day moving average is $81.58 and its 200-day moving average is $92.11. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.01. The company had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.61%. Medtronic’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Sell-side analysts anticipate that Medtronic PLC will post 5.97 earnings per share for the current year.

Medtronic Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be paid a dividend of $0.72 per share. The ex-dividend date is Friday, June 26th. This represents a $2.88 annualized dividend and a dividend yield of 3.5%. This is a boost from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).